Log in

NASDAQ:OCGNOcugen Stock Price, Forecast & News

0.00 (0.00 %)
(As of 04/5/2020 03:53 AM ET)
Today's Range
Now: $0.28
50-Day Range
MA: $0.41
52-Week Range
Now: $0.28
Volume943,592 shs
Average Volume1.54 million shs
Market Capitalization$4.48 million
P/E RatioN/A
Dividend YieldN/A
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Current SymbolNASDAQ:OCGN



Sales & Book Value

Annual SalesN/A
Book Value($0.44) per share


Net Income$-20,240,000.00


Market Cap$4.48 million
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable

Receive OCGN News and Ratings via Email

Sign-up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter.

Ocugen (NASDAQ:OCGN) Frequently Asked Questions

How has Ocugen's stock been impacted by COVID-19 (Coronavirus)?

Ocugen's stock was trading at $0.3612 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OCGN stock has decreased by 22.5% and is now trading at $0.28. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ocugen?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ocugen.

When is Ocugen's next earnings date?

Ocugen is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Ocugen.

What price target have analysts set for OCGN?

2 equities research analysts have issued 1 year price targets for Ocugen's shares. Their forecasts range from $1.25 to $2.00. On average, they anticipate Ocugen's stock price to reach $1.63 in the next twelve months. This suggests a possible upside of 480.4% from the stock's current price. View analysts' price targets for Ocugen.

Has Ocugen been receiving favorable news coverage?

Media headlines about OCGN stock have trended very negative recently, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ocugen earned a news impact score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutOcugen.

Are investors shorting Ocugen?

Ocugen saw a drop in short interest in March. As of March 13th, there was short interest totaling 676,700 shares, a drop of 11.0% from the February 27th total of 760,500 shares. Based on an average daily volume of 1,998,500 shares, the short-interest ratio is presently 0.3 days. Approximately 1.4% of the shares of the company are sold short. View Ocugen's Current Options Chain.

Who are some of Ocugen's key competitors?

What other stocks do shareholders of Ocugen own?

Who are Ocugen's key executives?

Ocugen's management team includes the following people:
  • Dr. Shankar Musunuri Ph.D., MBA, Founder, Chairman & CEO
  • Dr. Uday B. Kompella, Founder & Director
  • Dr. Rasappa Arumugham, Chief Scientific Officer
  • Ms. Kelly A. Beck M.B.A., P.M.P., SPHR, VP of Investor Relations & Admin.
  • Dr. Daniel M. Jorgensen M.D., MPH, MBA, Chief Medical Officer

What is Ocugen's stock symbol?

Ocugen trades on the NASDAQ under the ticker symbol "OCGN."

How do I buy shares of Ocugen?

Shares of OCGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ocugen's stock price today?

One share of OCGN stock can currently be purchased for approximately $0.28.

How big of a company is Ocugen?

Ocugen has a market capitalization of $4.48 million. The company earns $-20,240,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Ocugen employs 14 workers across the globe. View additional information about Ocugen.

What is Ocugen's official website?

The official website for Ocugen is http://ocugen.com/.

How can I contact Ocugen?

Ocugen's mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The company can be reached via phone at 484-328-4701 or via email at [email protected]

This page was last updated on 4/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel